NSE: ZYDUSLIFE · 6 October 2026
- Zydus Lifesciences Ltd shares moved higher today, trading up 1.80% at ₹1,159.50. The stock opened at ₹1,153.00 and oscillated within a day's range of ₹1,145.20 to ₹1,164.80.
- Zydus Lifesciences announced a partnership with MSN Laboratories to launch Riociguat Tablets across all five strengths as the first generic equivalent of Adempas in the United States. The product is indicated for treating pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer's 2025 annual report cited in the filing, global sales of the branded product were approximately EUR 745 million.
- Trading volume was 0.99 times the 20-day average daily volume.
Why is Zydus Lifesciences share price rising on 6 October 2026?
Zydus Lifesciences Ltd shares moved higher today, trading up 1.80% at ₹1,159.50. The stock opened at ₹1,153.00 and oscillated within a day's range of ₹1,145.20 to ₹1,164.80.
The broader market participated in a positive session, with the Nifty advancing 0.98%. Meanwhile, the relevant sectoral benchmark Nifty Pharma rose 1.66%, indicating that the stock's 1.80% gain was supported by broader momentum across pharmaceutical counters. Over the preceding five trading days, the stock had experienced a correction of 4.57%, positioning today's move as a partial recovery.
The price action coincides with recent operational updates from the company, including its recent partnership announcement with MSN Laboratories to launch the first generic version of Adempas in the U.S. market.
15.65 lakh shares traded by 6 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 15.82 lakh shares (0.99 times). The five-day average daily volume was 24.23 lakh shares. Separately, the NSE report for 5 October 2026 showed 7.84 lakh shares delivered, representing 49.23% of that day’s traded volume. The same report recorded 43,191 trades.
The stock moved up by 1.80% following a recent 5-day correction of 4.57%, finding support alongside a strong 1.66% gain in the Nifty Pharma index. While recent business updates such as the U.S. generic launch provide fundamental context, today's price action aligns closely with a broader sectoral recovery and a technical bounce from recent lows.
Latest Company Developments
Zydus Lifesciences announced a partnership with MSN Laboratories to launch Riociguat Tablets across all five strengths as the first generic equivalent of Adempas in the United States. The product is indicated for treating pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer's 2025 annual report cited in the filing, global sales of the branded product were approximately EUR 745 million.
First-to-market generic launches in regulated specialty categories expand the company's complex generics footprint and revenue potential in the U.S. market.
The USFDA concluded a cGMP inspection at the company's manufacturing plant located at SEZ II in Ahmedabad between September 21 and September 28, 2026. The inspection concluded with a single observation and contained no data integrity related observations. The company stated it will work closely with the regulator to address the observation expeditiously.
Regulatory compliance and clearance status for key manufacturing facilities are vital for maintaining uninterrupted export execution and approvals.
The company announced that an onsite USFDA inspection of pharmacovigilance and post-marketing surveillance systems at its U.S. office in New Jersey concluded with nil observations. The inspection was conducted from September 22 to September 25, 2026. This adds to the regulatory milestones for the company's operational compliance framework.
A clean inspection report reinforces the company's adherence to stringent post-marketing surveillance standards in international markets.
a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.12% on 30 June 2026. This compares with 4.92% on 18 June 2026, a change of +0.20 percentage points.
The filing reported 38 MF/UTI holders.
Research & Brokerage Views
Maintained an Outperform rating, focusing on new business buildout and complex product execution to drive long-term growth.
Raised target price following earnings but kept a Sell rating due to valuation considerations relative to expected growth.
Maintained a Neutral rating reflecting limited immediate upside potential from prevailing valuation levels.
What to Watch Next
- Execution and market uptake of the newly launched generic Riociguat tablets in the U.S.
- Company response and resolution timeline regarding the single USFDA observation at the Ahmedabad SEZ II plant
- Sustained delivery participation and cash volume relative to the 20-day moving average
- Performance trends within the Nifty Pharma index to gauge continued sector-wide sentiment
Other Dated Coverage
- Why Zydus Lifesciences Shares Fell 2.46% Today: Market Context | 1 October 2026 — 1 October 2026
- Why Zydus Lifesciences Shares Fell 3.21% Today: Sector Weakness | 30 September 2026 — 30 September 2026
More Zydus Lifesciences news and dated analysis →
Frequently Asked Questions
What is the latest Zydus Lifesciences company news?
Zydus Lifesciences announced a partnership with MSN Laboratories to launch Riociguat Tablets across all five strengths as the first generic equivalent of Adempas in the United States. The product is indicated for treating pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer's 2025 annual report cited in the filing, global sales of the branded product were approximately EUR 745 million.
How strong was Zydus Lifesciences’s trading volume?
15.65 lakh shares traded, 0.99 times the 20-day average daily volume. The price and volume data are dated 6 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Article by: WittyTrades Research Desk
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.